# Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms

> **NCT02026063** · PHASE3 · COMPLETED · sponsor: **Lexicon Pharmaceuticals** · enrollment: 124 (actual)

## Conditions studied

- Carcinoid Syndrome

## Interventions

- **DRUG:** Telotristat etiprate

## Key facts

- **NCT ID:** NCT02026063
- **Lead sponsor:** Lexicon Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01-14
- **Primary completion:** 2018-09-12
- **Final completion:** 2018-09-12
- **Target enrollment:** 124 (ACTUAL)
- **Last updated:** 2019-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02026063

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02026063, "Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02026063. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*